Verbatim response from Perplexity
The FDA has cracked down on mass-marketed compounded GLP-1s (semaglutide and tirzepatide) because national drug shortages have ended, making the production of "essentially a copy" of approved drugs illegal [1][7]. The agency issued 30 warning letters to telehealth companies and compounding pharmacies in early 2026 for misleadingly marketing these unapproved products as equivalents to FDA-approved drugs like Wegovy or Ozempic [6][8].
However, licensed 503A compounding pharmacies remain legal operators if they meet strict conditions: they must compoundpatient-specific medications based on a valid prescription from a licensed provider for a genuine medical need (e.g., an allergy to an inactive ingredient or a specific dosing adjustment) [5][10]. These pharmacies cannot mass-produce or market the drugs to the general public [5].
Who is still operating legally?
- State-licensed 503A pharmacies: These operate legally only when filling individual prescriptions for specific patients with documented medical needs, using FDA-registered active pharmaceutical ingredients (APIs) [5][11].
- Safe Harbor Limit: Under the April 2026 clarification, a 503A pharmacy faces minimal enforcement risk only if it fills no more than four prescriptions of a specific "essentially a copy" preparation per calendar month for that drug [4][9].
Who is not operating legally (or is under enforcement)?
- Mass-market telehealth companies and outsourcing facilities (503B): Entities like Hims & Hers and other platforms that sell compounded GLP-1s broadly to the public without a specific patient-specific medical need are now targeted by FDA enforcement [6].
- Bulk Compounders: Because semaglutide was removed from the shortage list in February 2025 and tirzepatide in December 2024, 503B outsourcing facilities are foreclosed from bulk compounding these agents as "essentially a copy" [4][7].
Approximately 67% of mass-market compounded GLP-1 prescriptions written in 2025 are now considered unfillable because the dispensing pharmacies have received warning letters or cease-and-desist orders [11]. If you have a current prescription, it remains legal only if your compounder is a 503A pharmacy operating within the patient-specific, low-volume limit [9][11].